4105 Share Price Performance
Recent 4105 News & Updates
No updates
TTY Biopharm Company Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 6.27
- Gross Margin
- 58.01%
- Net Profit Margin
- 25.66%
- Debt/Equity Ratio
- 21.8%
TTY Biopharm Company Limited Competitors
About 4105
- Founded
- 1960
- Employees
- n/a
- CEO
- WebsiteView website
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.3%
- 3 Months: 12.3%
- 1 Year: 6.6%
- Year to Date: 2.0%
Over the last 7 days, the market has remained flat, although notably the Energy sector gained 7.6% in that time. Meanwhile, the market is actually up 6.6% over the past year. Looking forward, earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading